SRRK result

After the event it went to +26.06% at its highest, and later to −7.96% at its lowest, against the close price before FDA decision.

The news wasMixed

Approval gives Scholar Rock its first product, with a broad label, a $310,000 annual price and a priority review voucher. Against that, the fracture warning had not been disclosed before, management wrongly told investors on the Sunday call that there were no post-marketing safety requirements, and with the binary risk gone the stock traded as a launch story that has not started yet.

Measured fromChart

The FDA approved apitegromab as ISEMBYLD after the close on 11 September 2026, 19 days before the deadline, with a broad label and a fracture warning. The stock jumped after hours, then closed the first session 6.42% lower and kept falling for a week.

What else moved the price

Most of the fall was stock-specific. On 14 September SRRK fell 6.42% while XBI rose 0.90%. On 15 September the company filed an 8-K correcting its Sunday call, confirming a pregnancy safety study and 15-day fracture reporting, and Barclays downgraded it to Equalweight while raising its target to $58 from $55. XBI fell 2.27% that day, which accounts for part of the 3.57% drop. Before the decision the stock had drifted down from the signal price with no apitegromab news, to a $53.86 low on 10 September.

What we said	What happened	Result
The FDA approves apitegromab by the 30 September action date, forecast at 78%, with 17% on a delay or narrow manufacturing response and 5% on a more serious rejection.	Approved, 19 days early. The FDA approved it as ISEMBYLD on 11 September 2026 for patients aged 2 and over already on an SMN2-targeted treatment, with a label not limited by SMA type or ability to walk, a warning for fractures and a priority review voucher.	Correct
Expected direction positive, with 68% confidence in a positive reaction.	Positive for one evening and negative after that. The stock spiked to $69.85 after hours within five minutes of the first print, 26.06% above the $55.41 close, but closed the first regular session, 14 September, at $51.85, down 6.42% from the $55.41 close before the approval, and 8.54% below the $56.69 signal price.	Incorrect
Expected move +8% to +15% on approval, close to the ±13% historical average.	Only the after-hours session reached it, and overshot: the first print was $59.00, 6.48% above the $55.41 close, and the spike to $69.85 was 26.06% above it, well past the top of the range. The regular session never came close. The high on 14 September was $56.90, 2.69% up, and the close was 6.42% down.	Incorrect
Options-implied move of about ±20.8% through the 16 October expiration, on a $57.80 reference price.	Used in both directions. The after-hours spike to $69.85 was 20.85% above the $57.80 reference, right at the edge. Then the lowest close, $46.65 on 18 September, was 19.29% below the $57.80 reference, and the 15 September low of $46.54 was 19.48% below it. The 16 October expiration has not yet been reached.	Correct on size
Action Watch: approval removes the binary risk, and the stock then trades on launch execution over months rather than in one session.	The right call. A reader who watched avoided the whole slide: from the $56.69 signal price the stock fell to $46.65 by 18 September, 17.71% lower, and closed 25 September at $48.63.	Correct
Positive scenario: clean approval and immediate launch, +8% to +15% with a possible test of $62 to $66.	The approval was clean enough on paper, with a broad label and a $310,000 annual price above what analysts had assumed. The $62 to $66 test happened only after hours, where the stock went straight through it to $69.85 and came back inside minutes. In regular trading the stock never went above $56.90 in the window.	Incorrect
Neutral scenario: approval with a narrower label, extra post-approval requirements or launch uncertainty, -5% to +5%.	This is closer to what the market traded. The label was not narrower, but it did come with post-approval requirements the company first said did not exist: a pregnancy safety study and 15-day reporting of every fracture case, confirmed in an 8-K on 15 September. The reaction was worse than the band: -6.42% on the first session.	Neutral scenario
Impact strength high.	High. Volume on 14 September was 4.05 million shares and 5.25 million on 15 September, against the roughly 1.1 million the card called average.	Correct
Estimated duration several weeks, with the first move inside one to three sessions and a longer repricing possible after a clean approval.	The repricing did last about a week, but downward. The stock fell for five straight sessions to a $46.65 close on 18 September, then steadied between $48 and $52.	Partly correct
Short interest of about 15% of float was exposed to short covering on approval.	No squeeze showed in regular trading. The only move up was the after-hours print, and the first session sold off on four times normal volume.	Incorrect
Other stocks: BIIB and NVS, whose SMA drugs could see the market expand or value shift, and NVO with a weaker connection through the old Catalent facility.	No reaction to speak of. On 14 September BIIB rose 0.10%, NVS 1.33% and NVO 0.88%, against XBI up 0.90% and SPY down 0.45%.	Did not show
Technical bias bullish, broken by a daily close below $51 and turned bearish by a close below $47.	Both levels went. The stock closed at $50.00 on 15 September, below $51, and at $46.65 on 18 September, below $47. By the card's own test the chart turned bearish within a week of the approval.	Incorrect
What the market may be missing: the platform read-through to infants, FSHD and weight-loss muscle preservation, and the launch-execution risk of a company that has never sold a drug.	Not testable yet. The first sales figures will not come until the third-quarter report. Barclays cut the stock to Equalweight on 15 September on the view that further gains now depend on beating launch expectations and on the pipeline beyond SMA, which is the risk side of this point.	Not yet testable

Price Table	Price (USD)	Change from signal	Change from lowest (regular session)	Change from close before FDA decision
After signal
Price at analysis (Regular session)31 Aug 2026, 14:28	56.69	—	+5.25%
Sat 5, Sun 6, Mon 7 - no trading
Lowest price (Regular session)10 Sept 2026, 13:32	53.86	−4.99%	—
Highest price (Regular session)02 Sept 2026, 13:37	58.10	+2.49%	+7.87%
Sat 5, Sun 6, Mon 7 - no trading
Close price before FDA decisionFri 11 Sept 2026, 20:00, close	55.41	−2.26%	+2.88%
After FDA decision (11 Sep 2026, 22:25 UTC)
Price after FDA decision (After-hours)11 Sept 2026, 22:45	59.00	+4.07%	+9.54%	+6.48%
Sat 12, Sun 13 - no trading
Price after FDA decision (Regular session)14 Sept 2026, 13:30	56.51	−0.32%	+4.92%	+1.99%
Lowest price (Regular session)14 Sept 2026, 19:41	51.58	−9.01%	−4.23%	−6.91%
Highest price (Regular session)14 Sept 2026, 13:30	56.90	+0.37%	+5.64%	+2.69%
Lowest price (After-hours)14 Sept 2026, 23:26	51.00	−10.04%	−5.31%	−7.96%
Highest price (After-hours)11 Sept 2026, 22:50	69.85	+23.21%	+29.69%	+26.06%
Sat 12, Sun 13 - no trading
Close price after FDA decisionMon 14 Sept 2026, 20:00, close	51.85	−8.54%	−3.73%	−6.42%
Sat 19, Sun 20 - no trading
Current price (Regular session)25 Sept 2026, 20:00	48.63	−14.22%	−9.71%	−12.24%

Recorded after the event and not edited since. Past moves are not a forecast of future ones.

SRRKScholar Rock Holding Corporation

Positive

FDA approves Scholar Rock's apitegromab as Isembyld, unlocking its first commercial drug launch

Event passedFri, 11 Sept 2026, 22:25

FDA and Clinical

StockThe company this write-up is about, with its ticker symbol.: SRRK, Scholar Rock Holding Corporation
PriceWhere the shares traded when this write-up was made, and the exact minute that price was struck.: $56.69, 14:28 31/August/2026
Event Date And TimeWhen the event is expected. Shown in your own time zone, or in UTC if you switch the clock at the top of the page. If the exact hour is not confirmed, you only see the date.: 22:25 11/September/2026
What else lands that dayOther news and events on the same day that could push the price around, and whether they help this trade, bury it, or work against it.: CrowdedThe decision came after the close on 11 September 2026, not on the crowded 30 September date, so the 30 September calendar no longer applies.
Expected Stock ReactionWhich way we expect the share price to go after the event. Positive means it rises, Negative means it falls, Mixed means it could go either way.: Positive
Technical biasWhat the chart alone suggests, ignoring the news. Rated Bullish, Neutral or Bearish.: Bullish
ActionWhat we suggest you do before the event. Buy, Watch or Avoid.: Watch
Catalyst confidenceHow sure we are that the event happens as described. Scored out of 100. Higher means more sure.: 100/100
Stock-reaction confidenceHow sure we are that the stock reacts the way we expect. Scored out of 100. Higher means more sure.: 68/100

Expected price move and durationHow far the share price may move because of this event, and how long that move may last.

Options-implied moveHow big a move options traders are paying for right now. This is the market's own estimate, not ours.: ±20.8%
Historical average moveHow much this stock moved on average after similar events in the past.: ±13%
Our expected moveOur own estimate of the move, after weighing the market's estimate, the past moves and the situation now.: +8% to +15%
ImpactHow big we think that move is for this stock. Rated Low, Medium or High.: High
Estimated durationHow long the move is likely to last, such as intraday, a few trading days, or several weeks.: Several weeks

Priced-in levelHow much of this news the share price already reflects. Rated Low, Medium or High. The higher it is, the less room the price has left to move.: High
Risk levelHow much can go wrong with this idea if the event surprises. Rated Low, Medium or High.: High
Other affected StocksOther companies that could move on the same news, such as suppliers and competitors.: BIIB , NVS , NVO

Company overviewHow good the company itself is, setting this event aside. Useful if you plan to hold the shares rather than trade the news.

Company qualityHow solid the business is overall. Rated Strong, Average or Weak.: Average
GrowthHow fast the company is growing its sales and profit. Rated Low, Medium or High.: High
Financial healthCash, debt, cash flow and profit margins, and whether the company keeps issuing new shares. Rated Strong, Average or Weak.: Average
ValuationWhat you pay today for what the company earns, next to its rivals and its own past. Rated Cheap, Fair or Expensive.: Expensive
RiskHow much could go wrong with the business over years. Rated Low, Medium or High. This is not Risk level above, which is about this one event.: High
Overall outlookOur long-term view of the company. Positive, Neutral or Negative. This is not Expected Stock Reaction, which covers one event.: Positive
Best suited forThe kind of investor this stock fits, such as someone holding for years or someone who wants income.: High-risk long-term biotech investors

Upcoming catalystThe event that could move the share price.

FDA decision on apitegromab for spinal muscular atrophy. The FDA approved it as Isembyld on 11 September 2026, 19 days before the 30 September 2026 deadline.

Main stock affectedThe company the event affects most directly.

Scholar Rock Holding Corporation, Nasdaq ticker SRRK.

Current priceWhere the shares traded when this write-up was made, and when that was.

$56.69 as of 31 Aug 2026, 14:28 UTC.

Expected stock reactionWhich way we expect the share price to go after the event. Positive means it rises, Negative means it falls, Mixed means it could go either way.

Positive. The FDA approved apitegromab as Isembyld on 11 September 2026. The previous rejection concerned a third-party fill-finish facility, not apitegromab's efficacy or safety, and the alternate facility Scholar Rock submitted cleared the review.

Action before the eventWhat we suggest you do before the event. Buy, Watch or Avoid.

Watch. The approval on 11 September 2026 removed the binary regulatory risk. The stock now trades on launch execution: pricing, reimbursement and early prescriptions, which arrive over months rather than in one session.

Why the stock is affectedThe link between the event and this company.

Scholar Rock has no product revenue yet. The FDA approved apitegromab, its lead asset, as Isembyld on 11 September 2026, which permits an immediate US launch and begins converting a research business into a commercial drug company. What the stock is worth now depends on how quickly that launch builds sales.

Catalyst confidenceHow sure we are that the event happens as described. Scored out of 100. Higher means more sure.

The event has happened. The FDA approved apitegromab as Isembyld on 11 September 2026, so confidence in the catalyst is 100%. The label covers people aged 2 and over who already take an SMN2-targeted treatment, and carries a warning about fracture risk.

Stock-reaction confidenceHow sure we are that the stock reacts the way we expect. Scored out of 100. Higher means more sure.

68% confidence that approval produces a positive reaction. The probability is lower than the approval confidence because a large part of the expected success appears reflected in the current valuation.

When the market will reactThe moment the price is likely to move, such as at the announcement or at the next market open.

The approval was announced after the US close on 11 September 2026, so the market reacted in the next regular session, on 14 September 2026.

Effect on the businessWhat the event changes for the company itself, such as its sales, costs or profit.

The approval creates Scholar Rock's first product revenue and lets its prepared US launch begin. Management estimates apitegromab has more than $2 billion in global revenue potential in SMA alone. The rejection case, which would have kept the company at zero revenue while costs continued, no longer applies.

Market expectations and forecastWhat investors already expect from this event, and the numbers being forecast.

The market broadly expected approval. The FDA's prior complete response letter was tied to Catalent Indiana manufacturing observations, with no cited efficacy or safety concern, and Scholar Rock said the alternate US facility had a strong compliance record and commercial vials were available. The forecast was a 78% approval probability, a 17% delay or narrow manufacturing-related response probability, and a 5% probability of a more serious rejection. The FDA approved it on 11 September 2026, ahead of the 30 September deadline.

How much is already priced inHow much of the expected outcome the share price already reflects before the event happens.

High. SRRK gained about 74% over the year through 28 August 2026 and traded close to its $61.76 52-week high. Its market value is approximately $7.4 billion despite having no product revenue. The market has also repeatedly been told that the FDA found no clinical approvability problem and that launch inventory is ready.

Expected price move and durationHow far the share price may move because of this event, and how long that move may last.

Options-Implied Move The 16 October 2026 options expiration, the first standard monthly expiration after the decision, indicated approximately ±20.8% using the midpoint cost of the near-the-money $60 call and put divided by the $57.80 reference share price. The ± figure measures expected size, not direction. Bid-ask spreads were wide, so treat this as an approximate market-implied range. Calculation: call midpoint $4.30 plus put midpoint $7.70 equals a $12.00 straddle. $12.00 divided by $57.80 equals 20.8%. Historical Event Analysis 23 September 2025, FDA complete response letter caused by the original fill-finish facility. Shares fell about 14% in premarket trading, with the main reaction occurring on the first session after disclosure. 31 March 2026, Scholar Rock resubmitted the apitegromab application with a second facility. Shares rose about 12% during the first session. Historical Average Move ±13%, based on two comparable regulatory events. Calculation: the average absolute move was 14% plus 12%, divided by two, which equals 13%. Past reactions went both ways. The sample is limited because apitegromab has had few directly comparable regulatory events. Our Expected Move +8% to +15% on approval. This is below the options-implied ±20.8% because approval is the expected result and SRRK is already near its high. It is close to the ±13% historical average. A rejection would likely produce a much larger negative move, but that is not my base case. Impact Strength High. The decision controls whether Scholar Rock can launch its first commercial product and begin generating product revenue. Estimated Duration Several weeks. The first move should occur within one to three sessions. A clean approval could develop into a longer repricing as investors assess the label, price, reimbursement, launch demand and early prescriptions.

Result needed for a big moveWhat the outcome has to be for the stock to move a lot instead of a little.

What counted was a clean approval, no restrictive manufacturing conditions, launch confirmation and a commercially usable label. The FDA approved apitegromab on 11 September 2026 for people aged 2 and over who already take an SMN2-targeted treatment, with a warning about fracture risk, and Scholar Rock said it would be available to ship within days. A priority review voucher would add value if the company received one; I cannot confirm whether it did.

Possible outcomesThe main ways the event could turn out, with the expected stock reaction for each one.

Positive scenario: Clean approval and immediate launch. Expected reaction is +8% to +15%, with a possible test of $62 to $66. Neutral scenario: Approval with a narrower label, extra post-approval requirements or launch uncertainty. Expected reaction is -5% to +5%. The negative scenario, another complete response letter or manufacturing delay, did not happen: the FDA approved apitegromab on 11 September 2026.

Other affected stocksOther companies that could move on the same news, such as suppliers and competitors.

BIIB and NVS. Biogen sells Spinraza and Novartis sells Zolgensma. Apitegromab is designed to improve muscle function and can be used alongside an SMN-targeted treatment, so it may expand the treated market while changing how value is divided among SMA therapies. NVO has a weaker connection because its Catalent Indiana facility caused the previous delay, but that facility has now been removed from the application.

What the market may be missingSomething we think investors have overlooked or read wrong.

The important upside is broader than the first SMA launch. Apitegromab is also being studied in infants, facioscapulohumeral muscular dystrophy and muscle preservation during weight loss. The approval on 11 September 2026 validates the myostatin platform and lowers perceived development risk for those programs. The overlooked risk is launch execution. Scholar Rock has never sold a drug, and prior authorization could slow early adoption even after approval.

What else lands that dayOther news and events on the same day that could push the price around, and whether they help this trade, bury it, or work against it.

This section described 30 September 2026, the FDA deadline. The decision came earlier, after the US close on Friday 11 September 2026, so the busy 30 September calendar of PCE inflation, the third GDP estimate and quarter-end rebalancing no longer bears on it. The first session to trade the approval was Monday 14 September 2026.

Main risksWhat could go wrong, and what would prove this call wrong.

Overall risk level is High. With approval granted, the main risks are now weak reimbursement, slow physician adoption, the fracture warning on the label, dilution, high cash burn or a broad biotech selloff. Launch execution rather than a regulatory decision now drives the stock.

Other factorsAnything else worth knowing that the sections above do not cover.

Short interest was about 18.2 million shares, or roughly 15% of float, in late August 2026. With approval granted on 11 September 2026, that positioning was exposed to short covering, and the case where it accelerates a decline on a failed approval no longer applies.

Trend over 6 to 12 monthsWhich way the share price has been heading over the past year, and how far it has travelled.

Rising. SRRK gained approximately 30.5% over six months and 74.0% over one year through 28 August 2026. The lowest closing price in the 52-week window was about $27.07 in November 2025. The highest closing price was $60.04 on 26 August 2026.

Recent price actionWhat the shares have done over the last few weeks and sessions, and on what kind of volume.

SRRK rose from $45.85 on 3 August 2026 to $57.80 on 28 August 2026, a 26.1% gain. It then declined from the $60.04 close on 26 August to $56.69 on 31 August, a 5.6% pullback. The 26 August session reached $61.76 on 2.28 million shares, more than twice the recent 30-day average. The current price sits about 85% of the way from the 52-week low to the 52-week high.

Market structureThe shape of the chart. Rising highs and rising lows mean an uptrend, falling ones mean a downtrend, and neither means the price is stuck in a range.

The medium-term structure is an uptrend with higher highs and higher lows. The shorter chart is consolidating between roughly $50 and $62. In simple terms, buyers have repeatedly appeared near the low-$50s, while sellers have appeared near $60 to $62.

Support and resistance zonesPrice areas where buyers have stepped in before, and price areas where sellers have. They often slow the price down when it gets there again.

First support is $54 to $55, tested several times during 18 to 21 August. A close below it would expose $51 to $52. Major support is $47 to $50, tested around the early-August earnings and regulatory updates. Resistance is $60 to $62, tested during 26 to 28 August. A strong close above $62 on heavy volume would confirm a new breakout.

50-day and 200-day moving averagesThe average closing price over the last 50 days and the last 200 days. Where the price sits against them shows whether the recent trend is strong or fading.

The 50-day simple moving average was $52.70 and the 200-day simple moving average was $47.01 using data through 28 August 2026. Price is above both, and both are rising. The 50-day is above the 200-day, which normally signals a positive medium-term trend. A moving average is simply the average closing price over the stated number of trading days. I cannot confirm the exact date when the 50-day last crossed above the 200-day.

Relative strengthHow this stock has performed against the wider market and against its own sector over the same period.

SRRK gained about 74.0% over one year. I cannot confirm matching one-year percentage returns for the S&P 500 and the biotechnology sector at the same timestamp. The available evidence shows SRRK was a strong absolute performer, but an exact relative-performance gap cannot be responsibly stated.

Volume trendHow many shares are changing hands lately compared with normal. Heavy volume behind a move means more traders agree with it.

The five completed sessions through 28 August averaged about 1.23 million shares. Calculation: 1.22 million, 1.21 million, 2.28 million, 0.62 million and 0.81 million divided by five. That was about 12% above the recent 1.10 million average. Volume supported the breakout attempt, especially on 26 August, but fell during the two-session pullback.

VolatilityHow much the share price swings day to day right now, compared with how much it usually swings.

The 14-day average true range was about $2.43, equal to 4.2% of the $57.80 reference price. This is high in absolute terms but close to SRRK's own recent normal range of roughly 4.1% to 4.6% daily volatility. Use a smaller position and a wider stop than you would use for a stable large company.

Long-Term Technical ViewThe wider chart over years. The big trend, the major price levels and how much the stock swings.

The three-year gain was more than 800%, but the route included severe drawdowns and regulatory gaps. Long-term support is around $27 to $30. The main long-term resistance is $60 to $62. The stock remains structurally bullish but highly volatile.

Technical biasWhat the chart alone suggests, ignoring the news. Rated Bullish, Neutral or Bearish.

Bullish. Price is above rising 50-day and 200-day averages, the stock has formed higher highs and higher lows, and the August advance had improving volume. This agrees with the positive catalyst view, although the catalyst carries more weight because an FDA decision can override the chart.

What would invalidate this biasThe price level or chart change that would prove the technical read wrong.

A daily close below $51 would break the recent higher-low structure. A close below $47 would turn the medium-term bias Bearish and suggest the August breakout had failed.

Technical data timestampWhen the chart figures above were taken. Markets keep moving, so check live charts before you trade.

31 August 2026, 14:28 UTC. The figures reflect the live regular US session through that time, with moving averages and completed-volume calculations based on data through 28 August 2026. Markets move after this report is written. Check a live chart and current levels before placing a trade.

Stock OverviewThe basic numbers. Price, size of the company, sector, the past year of highs and lows, trading volume and the next earnings date.

SRRK traded at $56.69 at 31 August 2026, 14:28 UTC. Market value was approximately $7.40 billion. It operates in the healthcare sector and biotechnology industry. The 52-week trading range was approximately $27.07 to $61.76. Recent 30-day average volume was about 1.10 million shares. The next earnings report is estimated for November 2026, but I cannot confirm an official company-announced date.

What the company doesThe business in plain words. What it sells, who buys it, and how the money reaches the company.

Scholar Rock develops antibodies that control growth-factor proteins. Its lead drug, apitegromab, approved by the FDA as Isembyld on 11 September 2026, blocks activation of myostatin, a protein that limits muscle growth. The simple example is that current SMA drugs help repair the signal sent to muscles, while apitegromab aims to help the muscle respond with more strength. The company has not yet reported product revenue.

Revenue BreakdownWhere the money comes from, split by product, by part of the business and by country.

Scholar Rock reported no revenue for the quarters ended 30 June 2025 and 30 June 2026. There is therefore no product, segment or geographic revenue to divide. The future business initially depends heavily on apitegromab. If its launch fails, there is no existing commercial revenue stream to absorb the damage.

Company GrowthHow sales, profit, earnings per share and spare cash have changed over the last few years.

Revenue was $0 in 2024, $0 in 2025 and $0 in the first half of 2026. Net loss widened from $246.3 million in 2024 to $377.9 million in 2025. The first-half 2026 net loss was $215.4 million. EPS was -$2.47 in 2024, -$3.29 in 2025 and -$1.67 for the first half of 2026. I cannot confirm a standardized free-cash-flow figure for every year. Financial growth has been negative, but potential commercial growth is high if apitegromab launches successfully.

Earnings PerformanceThe latest results, whether they beat or missed what the market expected, and what the company says comes next.

Second-quarter 2026 revenue was $0 and EPS was -$0.84, slightly better than the approximately -$0.85 market estimate. The corrected fourth-quarter 2025 EPS was -$0.76. Scholar Rock has not issued conventional revenue or profit guidance. It said it was prepared to launch apitegromab immediately after approval, and after the approval on 11 September 2026 it said the drug would be available to ship within days.

Financial HealthCash, debt, cash flow and profit margins, and whether the company keeps issuing new shares. Rated Strong, Average or Weak.

Cash, cash equivalents and marketable securities were $492.1 million at 30 June 2026. Long-term debt was $196.2 million, leaving approximately $295.9 million of net cash. Operating cash use was about $300.0 million in 2025. Gross and operating margins are not meaningful because revenue is zero. Second-quarter weighted average shares increased from 112.7 million in 2025 to 130.6 million in 2026, a 15.9% rise. The company can fund another difficult year, but continued delays would probably require more debt or equity. Financial health is Average.

ValuationWhat you pay today for what the company earns, next to its rivals and its own past. Rated Cheap, Fair or Expensive.

The trailing P/E ratio is not meaningful because earnings are negative. Forward P/E, PEG and EV-to-EBITDA are also not meaningful for a pre-revenue company with operating losses. These ratios normally show how much you pay for each dollar of earnings, but Scholar Rock has no earnings yet. At a market value near $7.4 billion against management's $2 billion-plus long-term SMA revenue opportunity, the valuation is Expensive. The approval on 11 September 2026 delivered the first part of what it assumes; the rest depends on successful commercialization.

ShareholdersWho owns the company. Big funds, company insiders, and whether ownership sits with only a few holders.

FMR was reported as the largest institutional holder at approximately 13.55% of shares as of 31 March 2026. Institutional ownership estimates vary because filings use different dates and can count pre-funded warrants differently. One late-August estimate placed conventional institutional ownership near 91%. Ownership is concentrated enough that major fund selling could move the price sharply.

Insider ActivityWhether the people running the company have been buying or selling their own shares lately.

Recent disclosed transactions were dominated by sales. CEO David Hallal sold 30,615 shares at $49.57 on 16 April 2026. Other executives sold smaller positions in February, April and July. I cannot confirm that these were all discretionary open-market decisions rather than scheduled or tax-related transactions. I found no confirmed material open-market insider purchase in the reviewed 2026 records.

Dividends and BuybacksCash paid out to shareholders, whether that payment looks safe, and whether the company is buying back its own shares.

Scholar Rock pays no dividend and has no confirmed active share-repurchase program. Retaining cash is normal for a pre-revenue biotechnology company. The company has instead issued shares through an at-the-market program to fund development and launch preparation.

Competitive PositionWho the company competes with, how much of the market it holds, and what it has that rivals do not.

The main SMA competitors are Biogen's Spinraza, Roche's Evrysdi and Novartis's Zolgensma. Apitegromab's distinction is that it targets muscle rather than the underlying SMN pathway. This could allow it to be added to existing therapy rather than forcing patients to switch. The advantage is promising but not yet commercially proven. It could weaken if reimbursement is restrictive or competing combination therapies produce similar benefits.

Future OutlookWhat sales and profit are expected to do next, and what management has promised.

Management estimates more than $2 billion in global apitegromab revenue potential from SMA and says roughly 35,000 patients have received an SMN-targeted therapy. The company has not provided a verified one-to-three-year revenue forecast. My view is that the approval on 11 September 2026 could create rapid early growth from a zero base, but payer reviews and physician education may make the first year slower than headline peak-sales estimates suggest.

Other Upcoming Company CatalystsOther events ahead that could move the share price, such as results, launches or approvals, apart from the catalyst this report is built on.

Potential catalysts after the main FDA event include the planned Japanese apitegromab application by the end of 2026, a European application resubmission using the alternate facility, Phase 1 SRK-439 data expected in the second half of 2026, progress from the OPAL infant SMA study and progress from the FORGE FSHD study. Exact dates are not confirmed.

Long-Term Company RisksWhat could weaken the business over the coming years, rather than around this one event.

The largest risk is dependence on apitegromab. Other risks include manufacturing reliance on third parties, no prior commercial-launch experience, payer resistance, slower adoption, high operating losses, debt, dilution and competition from established SMA companies. The share count has already increased materially. Product concentration worries me most because one regulatory or commercial failure could damage most of the company's value.

Traderavel VerdictOur straight answer on the company after everything above, not on the trade. Quality, growth, price, risk and the long-term view.

Scholar Rock is an Average-quality business today with High potential growth, Average financial health, an Expensive valuation and High long-term risk. Its science has produced strong late-stage evidence, and apitegromab was approved on 11 September 2026, but it has no commercial revenue yet and depends heavily on one product. My long-term outlook is Positive, and it now rests on proving the drug can build meaningful sales. The stock best suits high-risk long-term biotechnology investors who can tolerate large drawdowns. It does not suit income investors, conservative portfolios or anyone unable to withstand large swings during a first product launch.

For information only · not financial advice.

Expected price move and durationiHow far the share price may move because of this event, and how long that move may last.

Company overviewiHow good the company itself is, setting this event aside. Useful if you plan to hold the shares rather than trade the news.

Upcoming catalystiThe event that could move the share price.

Main stock affectediThe company the event affects most directly.

Current priceiWhere the shares traded when this write-up was made, and when that was.

Expected stock reactioniWhich way we expect the share price to go after the event. Positive means it rises, Negative means it falls, Mixed means it could go either way.

Action before the eventiWhat we suggest you do before the event. Buy, Watch or Avoid.

Why the stock is affectediThe link between the event and this company.

Catalyst confidenceiHow sure we are that the event happens as described. Scored out of 100. Higher means more sure.

Stock-reaction confidenceiHow sure we are that the stock reacts the way we expect. Scored out of 100. Higher means more sure.

When the market will reactiThe moment the price is likely to move, such as at the announcement or at the next market open.

Effect on the businessiWhat the event changes for the company itself, such as its sales, costs or profit.

Market expectations and forecastiWhat investors already expect from this event, and the numbers being forecast.

How much is already priced iniHow much of the expected outcome the share price already reflects before the event happens.

Expected price move and durationiHow far the share price may move because of this event, and how long that move may last.

Result needed for a big moveiWhat the outcome has to be for the stock to move a lot instead of a little.

Possible outcomesiThe main ways the event could turn out, with the expected stock reaction for each one.

Other affected stocksiOther companies that could move on the same news, such as suppliers and competitors.

What the market may be missingiSomething we think investors have overlooked or read wrong.

What else lands that dayiOther news and events on the same day that could push the price around, and whether they help this trade, bury it, or work against it.

Main risksiWhat could go wrong, and what would prove this call wrong.

Other factorsiAnything else worth knowing that the sections above do not cover.

Trend over 6 to 12 monthsiWhich way the share price has been heading over the past year, and how far it has travelled.

Recent price actioniWhat the shares have done over the last few weeks and sessions, and on what kind of volume.

Market structureiThe shape of the chart. Rising highs and rising lows mean an uptrend, falling ones mean a downtrend, and neither means the price is stuck in a range.

Support and resistance zonesiPrice areas where buyers have stepped in before, and price areas where sellers have. They often slow the price down when it gets there again.

50-day and 200-day moving averagesiThe average closing price over the last 50 days and the last 200 days. Where the price sits against them shows whether the recent trend is strong or fading.

Relative strengthiHow this stock has performed against the wider market and against its own sector over the same period.

Volume trendiHow many shares are changing hands lately compared with normal. Heavy volume behind a move means more traders agree with it.

VolatilityiHow much the share price swings day to day right now, compared with how much it usually swings.

Long-Term Technical ViewiThe wider chart over years. The big trend, the major price levels and how much the stock swings.

Technical biasiWhat the chart alone suggests, ignoring the news. Rated Bullish, Neutral or Bearish.

What would invalidate this biasiThe price level or chart change that would prove the technical read wrong.

Technical data timestampiWhen the chart figures above were taken. Markets keep moving, so check live charts before you trade.

Stock OverviewiThe basic numbers. Price, size of the company, sector, the past year of highs and lows, trading volume and the next earnings date.

What the company doesiThe business in plain words. What it sells, who buys it, and how the money reaches the company.

Revenue BreakdowniWhere the money comes from, split by product, by part of the business and by country.

Company GrowthiHow sales, profit, earnings per share and spare cash have changed over the last few years.

Earnings PerformanceiThe latest results, whether they beat or missed what the market expected, and what the company says comes next.

Financial HealthiCash, debt, cash flow and profit margins, and whether the company keeps issuing new shares. Rated Strong, Average or Weak.

ValuationiWhat you pay today for what the company earns, next to its rivals and its own past. Rated Cheap, Fair or Expensive.

ShareholdersiWho owns the company. Big funds, company insiders, and whether ownership sits with only a few holders.

Insider ActivityiWhether the people running the company have been buying or selling their own shares lately.

Dividends and BuybacksiCash paid out to shareholders, whether that payment looks safe, and whether the company is buying back its own shares.

Competitive PositioniWho the company competes with, how much of the market it holds, and what it has that rivals do not.

Future OutlookiWhat sales and profit are expected to do next, and what management has promised.

Other Upcoming Company CatalystsiOther events ahead that could move the share price, such as results, launches or approvals, apart from the catalyst this report is built on.

Long-Term Company RisksiWhat could weaken the business over the coming years, rather than around this one event.

Traderavel VerdictiOur straight answer on the company after everything above, not on the trade. Quality, growth, price, risk and the long-term view.

Expected price move and durationHow far the share price may move because of this event, and how long that move may last.

Company overviewHow good the company itself is, setting this event aside. Useful if you plan to hold the shares rather than trade the news.

Upcoming catalystThe event that could move the share price.

Main stock affectedThe company the event affects most directly.

Current priceWhere the shares traded when this write-up was made, and when that was.

Expected stock reactionWhich way we expect the share price to go after the event. Positive means it rises, Negative means it falls, Mixed means it could go either way.

Action before the eventWhat we suggest you do before the event. Buy, Watch or Avoid.

Why the stock is affectedThe link between the event and this company.

Catalyst confidenceHow sure we are that the event happens as described. Scored out of 100. Higher means more sure.

Stock-reaction confidenceHow sure we are that the stock reacts the way we expect. Scored out of 100. Higher means more sure.

When the market will reactThe moment the price is likely to move, such as at the announcement or at the next market open.

Effect on the businessWhat the event changes for the company itself, such as its sales, costs or profit.

Market expectations and forecastWhat investors already expect from this event, and the numbers being forecast.

How much is already priced inHow much of the expected outcome the share price already reflects before the event happens.

Expected price move and durationHow far the share price may move because of this event, and how long that move may last.

Result needed for a big moveWhat the outcome has to be for the stock to move a lot instead of a little.

Possible outcomesThe main ways the event could turn out, with the expected stock reaction for each one.

Other affected stocksOther companies that could move on the same news, such as suppliers and competitors.

What the market may be missingSomething we think investors have overlooked or read wrong.

What else lands that dayOther news and events on the same day that could push the price around, and whether they help this trade, bury it, or work against it.

Main risksWhat could go wrong, and what would prove this call wrong.

Other factorsAnything else worth knowing that the sections above do not cover.

Trend over 6 to 12 monthsWhich way the share price has been heading over the past year, and how far it has travelled.

Recent price actionWhat the shares have done over the last few weeks and sessions, and on what kind of volume.

Market structureThe shape of the chart. Rising highs and rising lows mean an uptrend, falling ones mean a downtrend, and neither means the price is stuck in a range.

Support and resistance zonesPrice areas where buyers have stepped in before, and price areas where sellers have. They often slow the price down when it gets there again.

50-day and 200-day moving averagesThe average closing price over the last 50 days and the last 200 days. Where the price sits against them shows whether the recent trend is strong or fading.

Relative strengthHow this stock has performed against the wider market and against its own sector over the same period.

Volume trendHow many shares are changing hands lately compared with normal. Heavy volume behind a move means more traders agree with it.

VolatilityHow much the share price swings day to day right now, compared with how much it usually swings.

Long-Term Technical ViewThe wider chart over years. The big trend, the major price levels and how much the stock swings.

Technical biasWhat the chart alone suggests, ignoring the news. Rated Bullish, Neutral or Bearish.

What would invalidate this biasThe price level or chart change that would prove the technical read wrong.

Technical data timestampWhen the chart figures above were taken. Markets keep moving, so check live charts before you trade.

Stock OverviewThe basic numbers. Price, size of the company, sector, the past year of highs and lows, trading volume and the next earnings date.

What the company doesThe business in plain words. What it sells, who buys it, and how the money reaches the company.

Revenue BreakdownWhere the money comes from, split by product, by part of the business and by country.

Company GrowthHow sales, profit, earnings per share and spare cash have changed over the last few years.

Earnings PerformanceThe latest results, whether they beat or missed what the market expected, and what the company says comes next.

Financial HealthCash, debt, cash flow and profit margins, and whether the company keeps issuing new shares. Rated Strong, Average or Weak.

ValuationWhat you pay today for what the company earns, next to its rivals and its own past. Rated Cheap, Fair or Expensive.

ShareholdersWho owns the company. Big funds, company insiders, and whether ownership sits with only a few holders.

Insider ActivityWhether the people running the company have been buying or selling their own shares lately.

Dividends and BuybacksCash paid out to shareholders, whether that payment looks safe, and whether the company is buying back its own shares.

Competitive PositionWho the company competes with, how much of the market it holds, and what it has that rivals do not.

Future OutlookWhat sales and profit are expected to do next, and what management has promised.

Other Upcoming Company CatalystsOther events ahead that could move the share price, such as results, launches or approvals, apart from the catalyst this report is built on.

Long-Term Company RisksWhat could weaken the business over the coming years, rather than around this one event.

Traderavel VerdictOur straight answer on the company after everything above, not on the trade. Quality, growth, price, risk and the long-term view.